These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27123798)

  • 21. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
    Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
    J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making Amends for the Opioid Epidemic.
    Sharfstein JM; Olsen Y
    JAMA; 2019 Apr; 321(15):1446-1447. PubMed ID: 30990541
    [No Abstract]   [Full Text] [Related]  

  • 23. The prescribing of buprenorphine by advanced practice addictions nurses.
    Strobbe S; Hobbins D
    J Addict Nurs; 2012 Feb; 23(1):82-3. PubMed ID: 22468667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system.
    Zhu Y; Coyle DT; Mohamoud M; Zhou E; Eworuke E; Dormitzer C; Staffa J
    Drug Alcohol Depend; 2018 Jun; 187():221-226. PubMed ID: 29680678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
    Wen H; Hockenberry JM; Borders TF; Druss BG
    Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
    Lofwall MR; Walsh SL
    J Addict Med; 2014; 8(5):315-26. PubMed ID: 25221984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit.
    Luo Q; Erikson CE
    JAMA; 2023 May; 329(20):1792-1794. PubMed ID: 37103912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients With Opioid Use Disorder Deserve Trained Providers.
    Weimer MB; Tetrault JM; Fiellin DA
    Ann Intern Med; 2019 Dec; 171(12):931-932. PubMed ID: 31766053
    [No Abstract]   [Full Text] [Related]  

  • 30. Steps physicians report taking to reduce diversion of buprenorphine.
    Yang A; Arfken CL; Johanson CE
    Am J Addict; 2013; 22(3):184-7. PubMed ID: 23617857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage.
    Barsky BA; Busch AB; Patel SY; Mehrotra A; Huskamp HA
    JAMA Netw Open; 2022 Jan; 5(1):e2142531. PubMed ID: 34989798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine clinics: an integrated and multidisciplinary approach to treating opioid dependence.
    Marshalek PJ; Sullivan CR
    W V Med J; 2010; 106(4 Spec No):60-3. PubMed ID: 21932755
    [No Abstract]   [Full Text] [Related]  

  • 34. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
    Cooper HLF; Cloud DH; Young AM; Freeman PR
    N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of NPs in medication-assisted treatment for opioid use disorder.
    Cotton BP; Ferszt GG
    Nurse Pract; 2018 May; 43(5):8. PubMed ID: 29668514
    [No Abstract]   [Full Text] [Related]  

  • 36. Buprenorphine and addiction: challenges for the pharmacist.
    Boatwright DE
    J Am Pharm Assoc (Wash); 2002; 42(3):432-8. PubMed ID: 12030630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?
    Poorman E
    N Engl J Med; 2021 May; 384(19):1783-1784. PubMed ID: 33983689
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.
    Nguyen TD; Gupta S; Ziedan E; Simon KI; Alexander GC; Saloner B; Stein BD
    JAMA Intern Med; 2021 Apr; 181(4):562-565. PubMed ID: 33346795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
    Andrilla CHA; Coulthard C; Larson EH
    Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.